The Translational Team Science Award (TTSA) supports hypothesis-driven translational studies associated with an ongoing or completed clinical trial that could lead to a next-phase clinical trial or future clinical application. By leveraging information from ongoing or completed clinical trials, research projects funded by the TTSA should address critical knowledge gaps in outcomes, validate key research and expand upon potential transformative results, or investigate novel findings.
Proposals must address one of the following priorities:
- Bladder cancer
- Colorectal cancer
- Kidney cancer
- Listeria vaccine for cancer
- Liver cancer
- Melanoma and other skin cancers
- Pancreatic cancer
- Pediatric brain tumors
- Stomach cancer
Funding & Duration
The maximum period of performance is 3 years.
The anticipated combined direct costs budgeted for the entire period of performance for the Initiating PI and each Partnering PI’s applications will not exceed US $1M (approx AUD $1.3M).
Funding may be used for salary, travel, research supplies, clinical research costs (excluding clinical trials).
The initiating Primary Investigator (PI) should be at or above the level of Assistant Professor or equivalent. Post-doctoral fellows are not eligible to be Partnering PIs.
The partnering PI(s) must be at or above the level of Assistant Professor (or equivalent).
Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply.
Submission Requirements & Due Dates
- 8 June 2016 – pre-proposal submitted via https://eBRAP.org.
- 30 August 2016 – full applications (by invitation only) submitted to the Research Branch for internal review.
- Grants Officer: Dr Don McMaster
- Email: email@example.com